Show simple item record

dc.contributor.authorZhang, Yinan
dc.contributor.authorGonzalez Caldito, Natalia
dc.contributor.authorShirani, Afsaneh
dc.contributor.authorSalter, Amber
dc.contributor.authorCutter, Gary
dc.contributor.authorCulpepper, William
dc.contributor.authorWallin, Mitchell
dc.contributor.authorKosa, Peter
dc.contributor.authorBielekova, Bibiana
dc.contributor.authorLublin, Fred
dc.contributor.authorStϋve, Olaf
dc.date.accessioned2020-11-03T17:22:51Z
dc.date.available2020-11-03T17:22:51Z
dc.date.issued2020-01-01
dc.identifier.urihttp://hdl.handle.net/10713/14021
dc.description.abstractBackground: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are approved for the treatment of disease activity and are effective in reducing relapses and new magnetic resonance imaging (MRI) lesions. However, disease activity generally subsides with time, and age-dependent changes in DMT efficacy are not well-established. We aimed to investigate whether age impacts the efficacy of DMTs in treating disease activity in patients with relapsing–remitting MS (RRMS). Methods: DMT efficacy related to age was assessed through a meta-analysis of clinical trials that evaluated the efficacy of DMTs in RRMS patients as measured by reductions in the annualized relapse rate (ARR), new T2 lesions, and gadolinium-enhanced lesions on MRI. Using the mean baseline patient age from each trial, a weighted linear regression was fitted to determine whether age was associated with treatment efficacy on a group level. Results: Group-level data from a total of 28,082 patients from 26 trials of 14 different DMTs were included in the meta-analysis. There were no statistically significant associations between age and reductions in ARR, new T2 lesions, and gadolinium-enhanced lesions of the treatment group compared with placebo. Conclusion: DMTs for RRMS show efficacy in treating disease activity independent of age as demonstrated by group-level data from DMT clinical trials. Nevertheless, clinical trials select for patients with baseline disease activity regardless of age, thereby not representing real-world patients with RRMS, where disease activity declines with age.en_US
dc.description.sponsorshipSanofi Genzymeen_US
dc.description.urihttps://doi.org/10.1177/1756286420969016en_US
dc.language.isoenen_US
dc.publisherSAGE Publications Inc.en_US
dc.relation.ispartofTherapeutic Advances in Neurological Disordersen_US
dc.subjectagingen_US
dc.subjectclinical trialsen_US
dc.subjectdisease-modifying therapiesen_US
dc.subjectmultiple sclerosisen_US
dc.titleAging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trialsen_US
dc.typeArticleen_US
dc.identifier.doi10.1177/1756286420969016
dc.source.volume13


This item appears in the following Collection(s)

Show simple item record